Publications

BibTex format

@article{Montuschi:2018:10.3389/fphar.2018.00258,
author = {Montuschi, P and Santini, G and Mores, N and Vignoli, A and Macagno, F and Shoreh, R and Tenori, L and Zini, G and Fuso, L and Mondino, C and Di, Natale C and D'Amico, A and Luchinat, C and Barnes, PJ and Higenbottam, T},
doi = {10.3389/fphar.2018.00258},
journal = {Frontiers in Pharmacology},
title = {Breathomics for assessing the effects of treatment and withdrawal with inhaled Beclomethasone/Formoterol in patients with COPD},
url = {http://dx.doi.org/10.3389/fphar.2018.00258},
volume = {9},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β2-agonist (LABA) fixed dose combination (FDC) using a multidimensional classification model including breathomics.Methods: A pilot, proof-of-concept, pharmacological study was undertaken in 14 COPD patients on maintenance treatment with inhaled fluticasone propionate/salmeterol (500/50 μg b.i.d.) for at least 8 weeks (visit 1). Patients received 2-week treatment with inhaled beclomethasone dipropionate/formoterol (100/6 μg b.i.d.) (visit 2), 4-week treatment with formoterol alone (6 μg b.i.d.) (visit 3), and 4-week treatment with beclomethasone/formoterol (100/6 μg b.i.d.) (visit 4). Exhaled breath analysis with two e-noses, based on different technologies, and exhaled breath condensate (EBC) NMR-based metabolomics were performed. Sputum cell counts, sputum supernatant and EBC prostaglandin E2 (PGE2) and 15-F2t-isoprostane, fraction of exhaled nitric oxide, and spirometry were measured.Results: Compared with formoterol alone, EBC acetate and sputum PGE2, reflecting airway inflammation, were reduced after 4-week beclomethasone/formoterol. Three independent breathomics techniques showed that extrafine beclomethasone/formoterol short-term treatment was associated with different breathprints compared with regular fluticasone propionate/salmeterol. Either ICS/LABA FDC vs. formoterol alone was associated with increased pre-bronchodilator FEF25−75% and FEV1/FVC (P = 0.008–0.029). The multidimensional model distinguished fluticasone propionate/salmeterol vs. beclomethasone/formoterol, fluticasone propionate/salmeterol vs. formoterol, and formoterol vs. beclomethasone/formoterol (accuracy > 70%, P < 0.01).Conclusions: Breathomics could be used for assessing ICS treatment and withdrawal in COPD patients. Large
AU  - Montuschi,P
AU  - Santini,G
AU  - Mores,N
AU  - Vignoli,A
AU  - Macagno,F
AU  - Shoreh,R
AU  - Tenori,L
AU  - Zini,G
AU  - Fuso,L
AU  - Mondino,C
AU  - Di,Natale C
AU  - D'Amico,A
AU  - Luchinat,C
AU  - Barnes,PJ
AU  - Higenbottam,T
DO  - 10.3389/fphar.2018.00258
PY  - 2018///
SN  - 1663-9812
TI  - Breathomics for assessing the effects of treatment and withdrawal with inhaled Beclomethasone/Formoterol in patients with COPD
T2  - Frontiers in Pharmacology
UR  - http://dx.doi.org/10.3389/fphar.2018.00258
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430204700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/60068
VL  - 9
ER  -

Download

Professor Sir Peter Barnes, FRS, FMedSci

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)